These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

395 related articles for article (PubMed ID: 19996582)

  • 21. Impact of Ga-68 DOTATOC PET/CT on the diagnosis and treatment of patients with multiple endocrine neoplasia.
    Froeling V; Elgeti F; Maurer MH; Scheurig-Muenkler C; Beck A; Kroencke TJ; Pape UF; Hamm B; Brenner W; Schreiter NF
    Ann Nucl Med; 2012 Nov; 26(9):738-43. PubMed ID: 22865406
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Intraoperative sonography in patients with colorectal cancer and resectable liver metastases on preoperative FDG-PET-CT.
    Wildi SM; Gubler C; Hany T; Petrowsky H; Clavien PA; Jochum W; Gerlach T; Fried M; Mullhaupt B
    J Clin Ultrasound; 2008 Jan; 36(1):20-6. PubMed ID: 17937421
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of
    Sawicki LM; Deuschl C; Beiderwellen K; Ruhlmann V; Poeppel TD; Heusch P; Lahner H; Führer D; Bockisch A; Herrmann K; Forsting M; Antoch G; Umutlu L
    Eur Radiol; 2017 Oct; 27(10):4091-4099. PubMed ID: 28439648
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prospective comparison of [18F]fluorodeoxyglucose positron emission tomography and computed tomography in patients with melanoma with palpable lymph node metastases: diagnostic accuracy and impact on treatment.
    Bastiaannet E; Wobbes T; Hoekstra OS; van der Jagt EJ; Brouwers AH; Koelemij R; de Klerk JM; Oyen WJ; Meijer S; Hoekstra HJ
    J Clin Oncol; 2009 Oct; 27(28):4774-80. PubMed ID: 19720925
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role and clinical value of EUS in a multimodality esophageal carcinoma staging program with CT and positron emission tomography.
    Pfau PR; Perlman SB; Stanko P; Frick TJ; Gopal DV; Said A; Zhang Z; Weigel T
    Gastrointest Endosc; 2007 Mar; 65(3):377-84. PubMed ID: 17321235
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In-line (18)F-fluorodeoxyglucose positron emission tomography with computed tomography (PET/CT) in patients with carcinoma of the sinus/nasal area and orbit.
    Wild D; Eyrich GK; Ciernik IF; Stoeckli SJ; Schuknecht B; Goerres GW
    J Craniomaxillofac Surg; 2006 Jan; 34(1):9-16. PubMed ID: 16343913
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Computed tomography, magnetic resonance imaging and 11C-metomidate positron emission tomography for evaluation of adrenal incidentalomas.
    Hennings J; Hellman P; Ahlström H; Sundin A
    Eur J Radiol; 2009 Feb; 69(2):314-23. PubMed ID: 18082990
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The value of PET, CT and in-line PET/CT in patients with gastrointestinal stromal tumours: long-term outcome of treatment with imatinib mesylate.
    Goerres GW; Stupp R; Barghouth G; Hany TF; Pestalozzi B; Dizendorf E; Schnyder P; Luthi F; von Schulthess GK; Leyvraz S
    Eur J Nucl Med Mol Imaging; 2005 Feb; 32(2):153-62. PubMed ID: 15690223
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Impact of peptide receptor radionuclide therapy on the 68Ga-DOTATOC-PET/CT uptake in normal tissue.
    Giesel FL; Stefanova M; Schwartz LH; Afshar-Oromieh A; Eisenhut M; Haberkorn U; Kratochwil C
    Q J Nucl Med Mol Imaging; 2013 Jun; 57(2):171-6. PubMed ID: 23370092
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Role of 68Ga-DOTATOC PET/CT in carcinoids.
    Jindal T; Kumar A; Kumar R; Dutta R
    Pathol Int; 2010 Feb; 60(2):143-4. PubMed ID: 20398201
    [No Abstract]   [Full Text] [Related]  

  • 31. Are contrast media required for (68)Ga-DOTATOC PET/CT in patients with neuroendocrine tumours of the abdomen?
    Mayerhoefer ME; Schuetz M; Magnaldi S; Weber M; Trattnig S; Karanikas G
    Eur Radiol; 2012 Apr; 22(4):938-46. PubMed ID: 22080251
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Role of (68)Ga-DOTATOC PET-CT in the diagnosis and staging of pancreatic neuroendocrine tumours.
    Kumar R; Sharma P; Garg P; Karunanithi S; Naswa N; Sharma R; Thulkar S; Lata S; Malhotra A
    Eur Radiol; 2011 Nov; 21(11):2408-16. PubMed ID: 21750886
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Radiation exposure of patients during 68Ga-DOTATOC PET/CT examinations].
    Hartmann H; Zöphel K; Freudenberg R; Oehme L; Andreeff M; Wunderlich G; Eisenhofer G; Kotzerke J
    Nuklearmedizin; 2009; 48(5):201-7. PubMed ID: 19639164
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of 68Ga-DOTATOC PET and 111In-DTPAOC (Octreoscan) SPECT in patients with neuroendocrine tumours.
    Buchmann I; Henze M; Engelbrecht S; Eisenhut M; Runz A; Schäfer M; Schilling T; Haufe S; Herrmann T; Haberkorn U
    Eur J Nucl Med Mol Imaging; 2007 Oct; 34(10):1617-26. PubMed ID: 17520251
    [TBL] [Abstract][Full Text] [Related]  

  • 36. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
    J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Thymic neuroendocrine tumour (carcinoid): clinicopathological features of four patients with different presentation.
    Dutta R; Kumar A; Julka PK; Mathur SR; Kaushal S; Kumar R; Jindal T; Suri V
    Interact Cardiovasc Thorac Surg; 2010 Dec; 11(6):732-6. PubMed ID: 20851876
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Peptide receptor radionuclide therapy of neuroendocrine tumors with (90)Y-DOTATOC: is treatment response predictable by pre-therapeutic uptake of (68)Ga-DOTATOC?
    Öksüz MÖ; Winter L; Pfannenberg C; Reischl G; Müssig K; Bares R; Dittmann H
    Diagn Interv Imaging; 2014 Mar; 95(3):289-300. PubMed ID: 24034971
    [TBL] [Abstract][Full Text] [Related]  

  • 39. 68Ga-DOTATOC versus 68Ga-DOTATATE PET/CT in functional imaging of neuroendocrine tumors.
    Poeppel TD; Binse I; Petersenn S; Lahner H; Schott M; Antoch G; Brandau W; Bockisch A; Boy C
    J Nucl Med; 2011 Dec; 52(12):1864-70. PubMed ID: 22072704
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan.
    Chen SH; Chang YC; Hwang TL; Chen JS; Chou WC; Hsieh CH; Yeh TS; Hsu JT; Yeh CN; Tseng JH; Chen TC; Yen TC
    J Formos Med Assoc; 2018 Jun; 117(6):480-487. PubMed ID: 28735662
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.